Journal of Clinical Immunology and Allergy

Abstract

The aim of this study was to monitor cell-based immune response developed by micro particulate ovarian cancer vaccine when administered via dissolving micro needles for transdermal routes in murine models and correlate it with tumor retardation observed in tumor challenge study. Immunotherapeutic strategies may serve as an alternative method to control the recurrence or progression of ovarian cancer. Therefore, we propose here micro particulate vaccine to treat as well as to prevent ovarian cancer. This vaccine resulted in tumor retardation when challenged with live tumor cells. Recently, we conducted a study to understand the mechanism by which the vaccine worked, where we compared humoral and cellular immune response with tumor suppression observed. We also checked the efficacy of the adjuvants to improve the efficacy of the vaccine. The micro particles were made up of cellulose polymers such as HPMC, CPD and EC. Alum and MF59 were used as adjuvants to enhance the immune response. The micro needles were formulated using polymers such as HPMCAS and PVA along with sugars such as maltose and trehalose for their dissolving properties.